nodes	percent_of_prediction	percent_of_DWPC	metapath
Amlexanox—FGF1—corneal epithelium—type 2 diabetes mellitus	0.0779	0.313	CbGeAlD
Amlexanox—FGF1—artery—type 2 diabetes mellitus	0.0169	0.0678	CbGeAlD
Amlexanox—FGF1—nerve—type 2 diabetes mellitus	0.0167	0.0673	CbGeAlD
Amlexanox—FGF1—endothelium—type 2 diabetes mellitus	0.0142	0.0573	CbGeAlD
Amlexanox—S100A13—Methylergometrine—Bromocriptine—type 2 diabetes mellitus	0.00997	0.724	CbGdCrCtD
Amlexanox—S100A13—cardiovascular system—type 2 diabetes mellitus	0.00952	0.0383	CbGeAlD
Amlexanox—S100A12—cardiovascular system—type 2 diabetes mellitus	0.00939	0.0378	CbGeAlD
Amlexanox—S100A13—adipose tissue—type 2 diabetes mellitus	0.00839	0.0338	CbGeAlD
Amlexanox—S100A12—adipose tissue—type 2 diabetes mellitus	0.00828	0.0333	CbGeAlD
Amlexanox—Liver function test abnormal—Acarbose—type 2 diabetes mellitus	0.00819	0.0385	CcSEcCtD
Amlexanox—FGF1—retina—type 2 diabetes mellitus	0.00693	0.0279	CbGeAlD
Amlexanox—FGF1—nephron tubule—type 2 diabetes mellitus	0.00652	0.0262	CbGeAlD
Amlexanox—PDE4D—cortex of kidney—type 2 diabetes mellitus	0.00597	0.024	CbGeAlD
Amlexanox—S100A13—liver—type 2 diabetes mellitus	0.00588	0.0237	CbGeAlD
Amlexanox—FGF1—cardiovascular system—type 2 diabetes mellitus	0.00586	0.0236	CbGeAlD
Amlexanox—S100A12—liver—type 2 diabetes mellitus	0.00581	0.0234	CbGeAlD
Amlexanox—FGF1—kidney—type 2 diabetes mellitus	0.00573	0.0231	CbGeAlD
Amlexanox—FGF1—cortex of kidney—type 2 diabetes mellitus	0.00558	0.0225	CbGeAlD
Amlexanox—PDE4D—adipose tissue—type 2 diabetes mellitus	0.00552	0.0222	CbGeAlD
Amlexanox—Liver function test abnormal—Pioglitazone—type 2 diabetes mellitus	0.00542	0.0255	CcSEcCtD
Amlexanox—FGF1—adipose tissue—type 2 diabetes mellitus	0.00517	0.0208	CbGeAlD
Amlexanox—PDE4A—adipose tissue—type 2 diabetes mellitus	0.00489	0.0197	CbGeAlD
Amlexanox—Gastrointestinal disorder—Miglitol—type 2 diabetes mellitus	0.00479	0.0225	CcSEcCtD
Amlexanox—PDE4B—islet of Langerhans—type 2 diabetes mellitus	0.00457	0.0184	CbGeAlD
Amlexanox—Gastrointestinal disorder—Tolbutamide—type 2 diabetes mellitus	0.00431	0.0203	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Chlorpropamide—type 2 diabetes mellitus	0.00392	0.0184	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Tolazamide—type 2 diabetes mellitus	0.00392	0.0184	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Linagliptin—type 2 diabetes mellitus	0.00388	0.0182	CcSEcCtD
Amlexanox—PDE4D—liver—type 2 diabetes mellitus	0.00387	0.0156	CbGeAlD
Amlexanox—S100A13—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.0038	0.276	CbGdCrCtD
Amlexanox—Gastrointestinal disorder—Acarbose—type 2 diabetes mellitus	0.00376	0.0177	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Nateglinide—type 2 diabetes mellitus	0.00363	0.0171	CcSEcCtD
Amlexanox—FGF1—liver—type 2 diabetes mellitus	0.00362	0.0146	CbGeAlD
Amlexanox—Nervous system disorder—Rosiglitazone—type 2 diabetes mellitus	0.00337	0.0159	CcSEcCtD
Amlexanox—Nausea—Miglitol—type 2 diabetes mellitus	0.00329	0.0155	CcSEcCtD
Amlexanox—Liver function test abnormal—Metformin—type 2 diabetes mellitus	0.00327	0.0154	CcSEcCtD
Amlexanox—Paraesthesia—Repaglinide—type 2 diabetes mellitus	0.00327	0.0154	CcSEcCtD
Amlexanox—PDE4B—pancreas—type 2 diabetes mellitus	0.00321	0.0129	CbGeAlD
Amlexanox—PDE4B—cortex of kidney—type 2 diabetes mellitus	0.00315	0.0127	CbGeAlD
Amlexanox—Gastrointestinal disorder—Repaglinide—type 2 diabetes mellitus	0.00314	0.0148	CcSEcCtD
Amlexanox—Headache—Tolbutamide—type 2 diabetes mellitus	0.00312	0.0147	CcSEcCtD
Amlexanox—Liver function test abnormal—Irbesartan—type 2 diabetes mellitus	0.00309	0.0145	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Rosiglitazone—type 2 diabetes mellitus	0.00297	0.014	CcSEcCtD
Amlexanox—Nausea—Tolbutamide—type 2 diabetes mellitus	0.00296	0.0139	CcSEcCtD
Amlexanox—PDE4B—adipose tissue—type 2 diabetes mellitus	0.00291	0.0117	CbGeAlD
Amlexanox—Headache—Tolazamide—type 2 diabetes mellitus	0.00284	0.0134	CcSEcCtD
Amlexanox—Headache—Chlorpropamide—type 2 diabetes mellitus	0.00284	0.0134	CcSEcCtD
Amlexanox—Nervous system disorder—Pioglitazone—type 2 diabetes mellitus	0.00283	0.0133	CcSEcCtD
Amlexanox—Headache—Linagliptin—type 2 diabetes mellitus	0.00281	0.0132	CcSEcCtD
Amlexanox—Nervous system disorder—Sitagliptin—type 2 diabetes mellitus	0.00275	0.0129	CcSEcCtD
Amlexanox—Paraesthesia—Glipizide—type 2 diabetes mellitus	0.0027	0.0127	CcSEcCtD
Amlexanox—Nausea—Tolazamide—type 2 diabetes mellitus	0.0027	0.0127	CcSEcCtD
Amlexanox—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.0027	0.0127	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Glipizide—type 2 diabetes mellitus	0.0026	0.0122	CcSEcCtD
Amlexanox—Nausea—Acarbose—type 2 diabetes mellitus	0.00259	0.0122	CcSEcCtD
Amlexanox—Pain—Glipizide—type 2 diabetes mellitus	0.00257	0.0121	CcSEcCtD
Amlexanox—Paraesthesia—Glimepiride—type 2 diabetes mellitus	0.00252	0.0119	CcSEcCtD
Amlexanox—Nausea—Nateglinide—type 2 diabetes mellitus	0.0025	0.0117	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Pioglitazone—type 2 diabetes mellitus	0.00249	0.0117	CcSEcCtD
Amlexanox—Liver function test abnormal—Ramipril—type 2 diabetes mellitus	0.00249	0.0117	CcSEcCtD
Amlexanox—Nervous system disorder—Bromocriptine—type 2 diabetes mellitus	0.00249	0.0117	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	0.00243	0.0114	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	0.00242	0.0114	CcSEcCtD
Amlexanox—Pain—Sitagliptin—type 2 diabetes mellitus	0.00239	0.0113	CcSEcCtD
Amlexanox—Headache—Repaglinide—type 2 diabetes mellitus	0.00228	0.0107	CcSEcCtD
Amlexanox—Paraesthesia—Bromocriptine—type 2 diabetes mellitus	0.00228	0.0107	CcSEcCtD
Amlexanox—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.00227	0.0107	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.00219	0.0103	CcSEcCtD
Amlexanox—Nausea—Repaglinide—type 2 diabetes mellitus	0.00216	0.0102	CcSEcCtD
Amlexanox—Headache—Rosiglitazone—type 2 diabetes mellitus	0.00215	0.0101	CcSEcCtD
Amlexanox—Paraesthesia—Glyburide—type 2 diabetes mellitus	0.00208	0.00979	CcSEcCtD
Amlexanox—PDE4B—liver—type 2 diabetes mellitus	0.00204	0.00822	CbGeAlD
Amlexanox—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.00204	0.00961	CcSEcCtD
Amlexanox—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.00204	0.0096	CcSEcCtD
Amlexanox—Stomatitis—Ramipril—type 2 diabetes mellitus	0.00203	0.00953	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.002	0.00941	CcSEcCtD
Amlexanox—Headache—Glipizide—type 2 diabetes mellitus	0.00189	0.00887	CcSEcCtD
Amlexanox—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.00187	0.00882	CcSEcCtD
Amlexanox—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.00187	0.00879	CcSEcCtD
Amlexanox—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.00185	0.00871	CcSEcCtD
Amlexanox—Headache—Pioglitazone—type 2 diabetes mellitus	0.00181	0.0085	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.0018	0.00845	CcSEcCtD
Amlexanox—Nausea—Glipizide—type 2 diabetes mellitus	0.00179	0.00841	CcSEcCtD
Amlexanox—Pain—Gliclazide—type 2 diabetes mellitus	0.00178	0.00837	CcSEcCtD
Amlexanox—Headache—Glimepiride—type 2 diabetes mellitus	0.00176	0.00828	CcSEcCtD
Amlexanox—Headache—Sitagliptin—type 2 diabetes mellitus	0.00175	0.00825	CcSEcCtD
Amlexanox—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.00172	0.00808	CcSEcCtD
Amlexanox—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.00171	0.00803	CcSEcCtD
Amlexanox—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.0017	0.00798	CcSEcCtD
Amlexanox—Nausea—Glimepiride—type 2 diabetes mellitus	0.00167	0.00785	CcSEcCtD
Amlexanox—Nausea—Sitagliptin—type 2 diabetes mellitus	0.00166	0.00783	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.00165	0.00776	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.00163	0.00767	CcSEcCtD
Amlexanox—Pain—Orlistat—type 2 diabetes mellitus	0.00162	0.0076	CcSEcCtD
Amlexanox—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.00161	0.00758	CcSEcCtD
Amlexanox—Headache—Bromocriptine—type 2 diabetes mellitus	0.00159	0.00747	CcSEcCtD
Amlexanox—Paraesthesia—Metformin—type 2 diabetes mellitus	0.00156	0.00735	CcSEcCtD
Amlexanox—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.00152	0.00713	CcSEcCtD
Amlexanox—Nausea—Bromocriptine—type 2 diabetes mellitus	0.00151	0.00708	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.0015	0.00707	CcSEcCtD
Amlexanox—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.00147	0.00694	CcSEcCtD
Amlexanox—Headache—Glyburide—type 2 diabetes mellitus	0.00145	0.00683	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.00142	0.00667	CcSEcCtD
Amlexanox—Pain—Irbesartan—type 2 diabetes mellitus	0.0014	0.00661	CcSEcCtD
Amlexanox—Paraesthesia—Losartan—type 2 diabetes mellitus	0.00139	0.00653	CcSEcCtD
Amlexanox—Nausea—Glyburide—type 2 diabetes mellitus	0.00138	0.00648	CcSEcCtD
Amlexanox—Pain—Losartan—type 2 diabetes mellitus	0.00132	0.00622	CcSEcCtD
Amlexanox—Headache—Gliclazide—type 2 diabetes mellitus	0.0013	0.00613	CcSEcCtD
Amlexanox—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.0013	0.00612	CcSEcCtD
Amlexanox—Nausea—Gliclazide—type 2 diabetes mellitus	0.00124	0.00581	CcSEcCtD
Amlexanox—Headache—Valsartan—type 2 diabetes mellitus	0.0012	0.00563	CcSEcCtD
Amlexanox—Paraesthesia—Ramipril—type 2 diabetes mellitus	0.00119	0.0056	CcSEcCtD
Amlexanox—Headache—Orlistat—type 2 diabetes mellitus	0.00118	0.00557	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.00114	0.00538	CcSEcCtD
Amlexanox—Nausea—Valsartan—type 2 diabetes mellitus	0.00114	0.00534	CcSEcCtD
Amlexanox—Nausea—Orlistat—type 2 diabetes mellitus	0.00112	0.00528	CcSEcCtD
Amlexanox—Headache—Metformin—type 2 diabetes mellitus	0.00109	0.00513	CcSEcCtD
Amlexanox—Nausea—Metformin—type 2 diabetes mellitus	0.00103	0.00486	CcSEcCtD
Amlexanox—Headache—Irbesartan—type 2 diabetes mellitus	0.00103	0.00484	CcSEcCtD
Amlexanox—Nausea—Irbesartan—type 2 diabetes mellitus	0.000976	0.00459	CcSEcCtD
Amlexanox—Headache—Losartan—type 2 diabetes mellitus	0.000968	0.00456	CcSEcCtD
Amlexanox—Nausea—Losartan—type 2 diabetes mellitus	0.000918	0.00432	CcSEcCtD
Amlexanox—Headache—Ramipril—type 2 diabetes mellitus	0.00083	0.00391	CcSEcCtD
Amlexanox—Nausea—Ramipril—type 2 diabetes mellitus	0.000787	0.0037	CcSEcCtD
Amlexanox—PDE4B—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	5.94e-05	0.000113	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.94e-05	0.000113	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	5.93e-05	0.000113	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.92e-05	0.000113	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	5.91e-05	0.000113	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.89e-05	0.000112	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—SRC—type 2 diabetes mellitus	5.84e-05	0.000111	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.83e-05	0.000111	CbGpPWpGaD
Amlexanox—FGF1—Disease—HIF1A—type 2 diabetes mellitus	5.8e-05	0.00011	CbGpPWpGaD
Amlexanox—FGF1—Disease—IRS2—type 2 diabetes mellitus	5.79e-05	0.00011	CbGpPWpGaD
Amlexanox—FGF1—Immune System—PRKCB—type 2 diabetes mellitus	5.78e-05	0.00011	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—LPL—type 2 diabetes mellitus	5.76e-05	0.00011	CbGpPWpGaD
Amlexanox—FGF1—Immune System—ICAM1—type 2 diabetes mellitus	5.76e-05	0.00011	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—APOB—type 2 diabetes mellitus	5.74e-05	0.000109	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.72e-05	0.000109	CbGpPWpGaD
Amlexanox—FGF1—Disease—CALM1—type 2 diabetes mellitus	5.68e-05	0.000108	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—HIF1A—type 2 diabetes mellitus	5.68e-05	0.000108	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—IRS2—type 2 diabetes mellitus	5.67e-05	0.000108	CbGpPWpGaD
Amlexanox—FGF1—Disease—APOE—type 2 diabetes mellitus	5.66e-05	0.000108	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—AGT—type 2 diabetes mellitus	5.66e-05	0.000108	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.65e-05	0.000108	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5.64e-05	0.000107	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	5.62e-05	0.000107	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—SRC—type 2 diabetes mellitus	5.6e-05	0.000107	CbGpPWpGaD
Amlexanox—FGF1—Disease—APOA1—type 2 diabetes mellitus	5.6e-05	0.000107	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—GNB3—type 2 diabetes mellitus	5.57e-05	0.000106	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CALM1—type 2 diabetes mellitus	5.57e-05	0.000106	CbGpPWpGaD
Amlexanox—IL3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.56e-05	0.000106	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—APOE—type 2 diabetes mellitus	5.55e-05	0.000106	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—LEP—type 2 diabetes mellitus	5.55e-05	0.000106	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.51e-05	0.000105	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—AVP—type 2 diabetes mellitus	5.5e-05	0.000105	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MMP3—type 2 diabetes mellitus	5.5e-05	0.000105	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.48e-05	0.000104	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—LPL—type 2 diabetes mellitus	5.48e-05	0.000104	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.47e-05	0.000104	CbGpPWpGaD
Amlexanox—FGF1—Immune System—IRS1—type 2 diabetes mellitus	5.47e-05	0.000104	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.47e-05	0.000104	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.45e-05	0.000104	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	5.4e-05	0.000103	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.39e-05	0.000103	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5.37e-05	0.000102	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—APOB—type 2 diabetes mellitus	5.31e-05	0.000101	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CCR5—type 2 diabetes mellitus	5.31e-05	0.000101	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.29e-05	0.000101	CbGpPWpGaD
Amlexanox—FGF1—Disease—NOS2—type 2 diabetes mellitus	5.28e-05	0.0001	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	5.24e-05	9.99e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.23e-05	9.96e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.23e-05	9.96e-05	CbGpPWpGaD
Amlexanox—S100A12—Immune System—EGFR—type 2 diabetes mellitus	5.21e-05	9.93e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.2e-05	9.91e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—GNB3—type 2 diabetes mellitus	5.2e-05	9.89e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—C3—type 2 diabetes mellitus	5.19e-05	9.88e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—CASP8—type 2 diabetes mellitus	5.16e-05	9.82e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.15e-05	9.8e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	5.14e-05	9.8e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—AVP—type 2 diabetes mellitus	5.13e-05	9.76e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MMP3—type 2 diabetes mellitus	5.13e-05	9.76e-05	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—EGFR—type 2 diabetes mellitus	5.11e-05	9.74e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.1e-05	9.72e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.08e-05	9.68e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—LPL—type 2 diabetes mellitus	5.07e-05	9.66e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—AKT2—type 2 diabetes mellitus	5.06e-05	9.64e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CCR5—type 2 diabetes mellitus	5.05e-05	9.62e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—IRS1—type 2 diabetes mellitus	5.05e-05	9.62e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.05e-05	9.61e-05	CbGpPWpGaD
Amlexanox—IL3—Immune System—IL6—type 2 diabetes mellitus	5e-05	9.52e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.97e-05	9.46e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—APOB—type 2 diabetes mellitus	4.95e-05	9.43e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.95e-05	9.42e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.95e-05	9.42e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—C3—type 2 diabetes mellitus	4.94e-05	9.4e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.93e-05	9.4e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	4.93e-05	9.4e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—AGT—type 2 diabetes mellitus	4.93e-05	9.38e-05	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—EGFR—type 2 diabetes mellitus	4.91e-05	9.35e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—EDN1—type 2 diabetes mellitus	4.88e-05	9.28e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.85e-05	9.23e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—INS—type 2 diabetes mellitus	4.84e-05	9.21e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—LEP—type 2 diabetes mellitus	4.83e-05	9.19e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—APOE—type 2 diabetes mellitus	4.83e-05	9.19e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—SRC—type 2 diabetes mellitus	4.8e-05	9.14e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.77e-05	9.09e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.76e-05	9.06e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—INS—type 2 diabetes mellitus	4.74e-05	9.02e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—LPL—type 2 diabetes mellitus	4.73e-05	9.01e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.71e-05	8.97e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.7e-05	8.94e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—AGT—type 2 diabetes mellitus	4.69e-05	8.93e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—AKT2—type 2 diabetes mellitus	4.68e-05	8.9e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.67e-05	8.9e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.67e-05	8.9e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.66e-05	8.88e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.63e-05	8.82e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.61e-05	8.78e-05	CbGpPWpGaD
Amlexanox—IL3—Immune System—AKT1—type 2 diabetes mellitus	4.61e-05	8.78e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—LEP—type 2 diabetes mellitus	4.6e-05	8.75e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—APOE—type 2 diabetes mellitus	4.6e-05	8.75e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—PIK3R1—type 2 diabetes mellitus	4.59e-05	8.75e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.58e-05	8.73e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.58e-05	8.72e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—C3—type 2 diabetes mellitus	4.57e-05	8.7e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.56e-05	8.68e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.55e-05	8.67e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.54e-05	8.65e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—SERPINE1—type 2 diabetes mellitus	4.44e-05	8.46e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.44e-05	8.45e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—BCL2—type 2 diabetes mellitus	4.42e-05	8.42e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.36e-05	8.3e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.36e-05	8.3e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.35e-05	8.29e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.35e-05	8.27e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—AGT—type 2 diabetes mellitus	4.34e-05	8.26e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.33e-05	8.25e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—RELA—type 2 diabetes mellitus	4.32e-05	8.24e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.31e-05	8.2e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.29e-05	8.17e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.27e-05	8.13e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—C3—type 2 diabetes mellitus	4.26e-05	8.11e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—LEP—type 2 diabetes mellitus	4.25e-05	8.1e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—APOE—type 2 diabetes mellitus	4.25e-05	8.1e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—PIK3R1—type 2 diabetes mellitus	4.24e-05	8.08e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—NOS3—type 2 diabetes mellitus	4.24e-05	8.08e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.21e-05	8.01e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.2e-05	8e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.16e-05	7.91e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.16e-05	7.91e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—INS—type 2 diabetes mellitus	4.13e-05	7.85e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.1e-05	7.81e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.06e-05	7.73e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.06e-05	7.73e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.05e-05	7.72e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—AGT—type 2 diabetes mellitus	4.05e-05	7.71e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.01e-05	7.64e-05	CbGpPWpGaD
Amlexanox—S100A12—Immune System—IL6—type 2 diabetes mellitus	4.01e-05	7.63e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.99e-05	7.6e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.99e-05	7.59e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.98e-05	7.58e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.97e-05	7.56e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—LEP—type 2 diabetes mellitus	3.97e-05	7.55e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—APOE—type 2 diabetes mellitus	3.97e-05	7.55e-05	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—IL6—type 2 diabetes mellitus	3.93e-05	7.48e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—INS—type 2 diabetes mellitus	3.93e-05	7.48e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.92e-05	7.46e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—RELA—type 2 diabetes mellitus	3.91e-05	7.45e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—PTGS2—type 2 diabetes mellitus	3.88e-05	7.39e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.86e-05	7.36e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.8e-05	7.23e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.8e-05	7.23e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.79e-05	7.22e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.79e-05	7.21e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.78e-05	7.2e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.74e-05	7.12e-05	CbGpPWpGaD
Amlexanox—S100A12—Immune System—AKT1—type 2 diabetes mellitus	3.7e-05	7.04e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—NFKB1—type 2 diabetes mellitus	3.65e-05	6.94e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—INS—type 2 diabetes mellitus	3.63e-05	6.92e-05	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—AKT1—type 2 diabetes mellitus	3.63e-05	6.9e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.62e-05	6.89e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.62e-05	6.89e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.61e-05	6.87e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.57e-05	6.81e-05	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.56e-05	6.78e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.54e-05	6.74e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.53e-05	6.72e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.51e-05	6.69e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.51e-05	6.69e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.51e-05	6.67e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.5e-05	6.66e-05	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—AKT1—type 2 diabetes mellitus	3.48e-05	6.63e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.44e-05	6.56e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.44e-05	6.56e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—RELA—type 2 diabetes mellitus	3.4e-05	6.48e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—SRC—type 2 diabetes mellitus	3.4e-05	6.47e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—INS—type 2 diabetes mellitus	3.39e-05	6.45e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.34e-05	6.35e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.33e-05	6.35e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.33e-05	6.35e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.3e-05	6.28e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.28e-05	6.24e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.27e-05	6.23e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—RELA—type 2 diabetes mellitus	3.24e-05	6.17e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.23e-05	6.16e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—IL6—type 2 diabetes mellitus	3.23e-05	6.15e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.19e-05	6.07e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.19e-05	6.07e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—SRC—type 2 diabetes mellitus	3.14e-05	5.98e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.11e-05	5.92e-05	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.1e-05	5.9e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—SRC—type 2 diabetes mellitus	3.07e-05	5.85e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.07e-05	5.85e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.05e-05	5.81e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—RELA—type 2 diabetes mellitus	3e-05	5.71e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.99e-05	5.7e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.98e-05	5.68e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—EGFR—type 2 diabetes mellitus	2.98e-05	5.67e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.97e-05	5.66e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.97e-05	5.66e-05	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.95e-05	5.62e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.92e-05	5.57e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.9e-05	5.53e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.9e-05	5.53e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.87e-05	5.47e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.81e-05	5.36e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—TGFB1—type 2 diabetes mellitus	2.81e-05	5.34e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.8e-05	5.32e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.76e-05	5.26e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—EGFR—type 2 diabetes mellitus	2.75e-05	5.24e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.75e-05	5.23e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.73e-05	5.2e-05	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.73e-05	5.2e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.7e-05	5.15e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.69e-05	5.13e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.69e-05	5.12e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.68e-05	5.1e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—SRC—type 2 diabetes mellitus	2.68e-05	5.1e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.61e-05	4.96e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.56e-05	4.87e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—SRC—type 2 diabetes mellitus	2.55e-05	4.85e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.53e-05	4.82e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.52e-05	4.8e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.48e-05	4.72e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.48e-05	4.72e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.39e-05	4.55e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.38e-05	4.54e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.36e-05	4.49e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—SRC—type 2 diabetes mellitus	2.36e-05	4.49e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.35e-05	4.47e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.3e-05	4.37e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—IL6—type 2 diabetes mellitus	2.29e-05	4.36e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.28e-05	4.34e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.23e-05	4.25e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.2e-05	4.18e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.14e-05	4.08e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—IL6—type 2 diabetes mellitus	2.11e-05	4.02e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—AKT1—type 2 diabetes mellitus	2.11e-05	4.02e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.11e-05	4.01e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—IL6—type 2 diabetes mellitus	2.07e-05	3.94e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.07e-05	3.93e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.96e-05	3.74e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—AKT1—type 2 diabetes mellitus	1.95e-05	3.71e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.93e-05	3.67e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.91e-05	3.64e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—IL6—type 2 diabetes mellitus	1.8e-05	3.43e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.72e-05	3.27e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.66e-05	3.17e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IL6—type 2 diabetes mellitus	1.59e-05	3.02e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.58e-05	3.01e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.48e-05	2.82e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.46e-05	2.79e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.37e-05	2.6e-05	CbGpPWpGaD
